<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.2" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>RBlog &#187; Tijana Ignjatovic</title>
	<link>http://www.reportbuyer.com/blog</link>
	<description>Sharing intelligence</description>
	<pubDate>Thu, 20 Nov 2008 14:57:29 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2</generator>
	<language>en</language>
			<item>
		<title>Is drug lifecycle management the answer to the $100billion question?</title>
		<link>http://www.reportbuyer.com/blog/is-drug-lifecycle-management-the-answer-to-the-100billion-question/</link>
		<comments>http://www.reportbuyer.com/blog/is-drug-lifecycle-management-the-answer-to-the-100billion-question/#comments</comments>
		<pubDate>Tue, 26 Aug 2008 13:17:42 +0000</pubDate>
		<dc:creator>Tijana Ignjatovic</dc:creator>
		
		<category><![CDATA[Pharma &amp; Healthcare]]></category>
<category>Pharma &amp;amp; Healthcare</category>
		<guid isPermaLink="false">http://www.reportbuyer.com/blog/is-drug-lifecycle-management-the-answer-to-the-100billion-question/</guid>
		<description><![CDATA[As competitive pressure from the post-patent-expiry entry of generics and new brands onto the market mounts, drug product lifecycles are becoming shorter and shorter with lower peak sales – a double edged sword for pharmaceutical companies. In fact, products worth more than $100 billion in sales (1) will be going off-patent and subject to generic [...]]]></description>
		<wfw:commentRss>http://www.reportbuyer.com/blog/is-drug-lifecycle-management-the-answer-to-the-100billion-question/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Despite Challenges- Big Pharma Companies Turn Attention to Emerging Markets</title>
		<link>http://www.reportbuyer.com/blog/despite-challenges-big-pharma-companies-turn-attention-to-emerging-markets/</link>
		<comments>http://www.reportbuyer.com/blog/despite-challenges-big-pharma-companies-turn-attention-to-emerging-markets/#comments</comments>
		<pubDate>Wed, 19 Mar 2008 15:41:47 +0000</pubDate>
		<dc:creator>Tijana Ignjatovic</dc:creator>
		
		<category><![CDATA[Pharma &amp; Healthcare]]></category>
<category>disposable income</category><category>double digit growth</category><category>economic booms</category><category>emerging markets</category><category>emerging market countries</category><category>foothold</category><category>health provision</category><category>mature markets</category><category>middle class</category><category>Pharma &amp;amp; Healthcare</category><category>pharmaceutical companies</category><category>pharmaceutical market</category><category>pharmaceutical markets</category><category>pharma companies</category><category>public provision</category><category>purchasing power</category><category>rapid economic growth</category><category>sustainable sources</category>
		<guid isPermaLink="false">http://www.reportbuyer.com/blog/despite-challenges-big-pharma-companies-turn-attention-to-emerging-markets/</guid>
		<description><![CDATA[Faced with dwindling growth rates in the US and Europe, pharmaceutical companies are turning their attention towards emerging pharmaceutical markets whose double-digit growth is fuelled by their recent economic booms. However, although the patient potential of the emerging market countries is enormous, foreign pharma companies are currently tapping into only a fraction of the consumers, [...]]]></description>
		<wfw:commentRss>http://www.reportbuyer.com/blog/despite-challenges-big-pharma-companies-turn-attention-to-emerging-markets/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
